# Z-Alpha Therapeutics

Source: https://onco.cc/companies/z-alpha-therapeutics/  
OnCo record `z-alpha-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Z-Alpha Therapeutics, in San Diego, is developing cancer drugs that carry a radioactive atom, astatine-211, to tumour cells to destroy them from close range. Its first drug, for prostate cancer, has had an early study in China.

## Summary

Z-Alpha Therapeutics develops targeted alpha radiotherapeutics based on the isotope astatine-211, which it says has a 7.2-hour half-life, emits one alpha particle per decay, decays to stable lead-207 and can be made on demand from bismuth. It says it has a stable supply of astatine-211 across several continents and its own labelling and linker technology. Its co-founders include chief executive Kevin Bunker, a co-founder of Zentalis Pharmaceuticals, chief technology officer Michael Zalutsky and scientific adviser Martin Pomper; its board includes representatives of OrbiMed, Tybourne Capital, Lilly Asia Ventures and D&D Pharmatech. A February 2026 Asia Business Daily report describes an astatine-211 PSMA-targeting candidate for prostate cancer, as developed by D&D Pharmatech's US affiliate Z-Alpha, says an initial clinical study was run in China and that US or European development was planned for 2026. OrbiMed's portfolio page describes Z-Alpha as Shanghai-based and as having licensed clinical-stage programmes from Zentalis, which differs from the company's current site.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Z-Alpha
- HQ: San Diego, CA
- Type: radiopharma
- Website: https://z-alpha.com/

## Notes

- OrbiMed's description (Shanghai-based, licensed clinical programmes from Zentalis) does not match the current website (San Diego, astatine-211 radiotherapeutics). The record follows the company's own site; the history between the two descriptions was not found.
- That candidate is not named on the company's own site and no ClinicalTrials.gov record was found, so no product record, cancer or PSMA target is linked.
- Founding year and financing amounts not stated.

## Sources

- Official website: https://z-alpha.com/
- Report on Z-Alpha's PSMA candidate and European patent (Asia Business Daily, February 2026): https://view.asiae.co.kr/en/article/2026020909521368429
- OrbiMed portfolio entry: https://www.orbimed.com/portfolio/

## Connected records

- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Astatine-211 alpha therapy](https://onco.cc/technologies/astatine-211-alpha-therapy/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- companies: [OrbiMed](https://onco.cc/companies/orbimed/)

---
JSON: https://onco.cc/api/v1/entities/z-alpha-therapeutics.json